Less than 10% of individuals eligible to benefit from weight-loss injections such as Wegovy have access to them, warns the WHO as it publishes its initial guidance on the therapies.
With more than one billion individuals worldwide currently living with obesity, it is calling for increased and just availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidance acknowledges that obesity is a lifelong illness that can be managed with comprehensive and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key hurdles to universal access to the jabs that can assist patients in reducing considerable weight, says the organization.
Skinny Jab Supply Crisis
Even under the present most optimistic case, the supply of GLP-1 therapies could only cover about 100 million people – less than 10% of those who need them, according to the health organization.
The guideline calls on nations and manufacturers to widen availability, by measures such as patent sharing.
The intellectual property rights on the active ingredient – the main component of a leading brand – is scheduled to end in several nations in 2026.
How Weight-Loss Injections Function
GLP-1 drugs imitate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so people reduce food intake.
Patients usually begin shedding pounds in the initial weeks of starting on the weekly injections.
Evidence indicates patients may regain a significant portion a year later of stopping the medication, when their typical food cravings resume.
Being above a healthy weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and specific cancers.
Excess weight concerns individuals in every country and was associated with millions of deaths worldwide in 2024, according to the WHO.
